Drugs / KK2223
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07192471 | Aug 2026 → Mar 2029 expected | T-cell non-Hodgkin lymphoma | Kyowa Kirin, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KK2223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07192471 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT07192471 ↗ |